^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2020
    Title:

    Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

    Published date:
    05/13/2020
    Excerpt:
    A trend of improved OS for D+T vs CT (HR 0.19; 95% CI 0.03–1.03) was also seen in pts with ATM mutations.
    DOI:
    10.1200/JCO.2020.38.15_suppl.6511
    Trial ID:
    EAGLE
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

    Published date:
    05/13/2020
    Excerpt:
    Pts with mutations in ATM (5%), a DNA damage repair gene, also trended with prolonged OS.
    DOI:
    10.1200/JCO.2020.38.15_suppl.6548
    Trial ID:
    HAWK; NCT02319044